Back to Forecasting
TEM Forecast Markets
Tempus AI, Inc.
7
Active Markets
50%
Avg Probability
All Markets
7 markets
Will Tempus AI report FY2026 revenue at or above $1.59B guidance?
78%
Likely Yes
85% agreement
Mar 15, 2027
IG: 0.00
Will Tempus migrate majority (>50%) of xT CDx volume to FDA-approved version by Q4 2026?
65%
Likely Yes
78% agreement
Mar 15, 2027
IG: 0.00
Will the TEM securities class action (AI-washing) survive the motion to dismiss by December 31, 2026?
35%
Likely No
72% agreement
Jan 15, 2027
IG: 0.00
Will Tempus receive MolDX coverage for its CRC MRD assay by September 30, 2026?
52%
Likely Yes
68% agreement
Oct 15, 2026
IG: 0.00
Will Tempus AI report FY2026 adjusted EBITDA at or above $65M guidance?
72%
Likely Yes
80% agreement
Mar 15, 2027
IG: 0.00
Will Tempus report any single quarter of FY2026 with AI algorithm/application revenue exceeding $50M?
8%
Likely No
92% agreement
Mar 15, 2027
IG: 0.00
Will Tempus report average genomics ASP above $1,800 for any quarter in H1 2026?
38%
Likely No
75% agreement
Sep 15, 2026
IG: 0.00
Resolution Timeline
Sep 15, 2026
Will Tempus report average genomics ASP above $1,800 for any quarter in H1 2026?Prediction: 38%
Oct 15, 2026
Will Tempus receive MolDX coverage for its CRC MRD assay by September 30, 2026?Prediction: 52%
Jan 15, 2027
Will the TEM securities class action (AI-washing) survive the motion to dismiss by December 31, 2026?Prediction: 35%
Mar 15, 2027
Will Tempus migrate majority (>50%) of xT CDx volume to FDA-approved version by Q4 2026?Prediction: 65%
Mar 15, 2027
Will Tempus report any single quarter of FY2026 with AI algorithm/application revenue exceeding $50M?Prediction: 8%